Fore scores $75M Se­ries D, tees up new lead­er­ship with ex-El­e­va­tion CEO Shawn Le­land at the helm — for now

Fore Bio­ther­a­peu­tics has reeled in a $75 mil­lion Se­ries D, and its CEO Matthew Ros is walk­ing off the course for “oth­er pro­fes­sion­al pur­suits,” the Philadel­phia drug de­vel­op­er said Wednes­day morn­ing.

Orig­i­nal­ly an Is­raeli di­ag­nos­tics com­pa­ny known as Nov­el­lus, Fore made the tran­si­tion to phar­ma­ceu­ti­cals a few years ago, dri­ven in part by its li­cens­ing of a Dai­ichi Sankyo BRAF in­hibitor in 2020.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER